Vuse Alto Unaffected by FDA Recent Decision | Vuse

The U.S. Food and Drug Administration (FDA) denied premarket tobacco product applications (PMTA) for our Vuse Solo Replacement Cartridge Menthol 4.8%.

• This denial does not impact the legal status of Vuse Alto’s PMTA, which is awaiting further review by FDA.
• This denial also does not impact the prior marketing authorizations for the Vuse Solo Power Unit and Vuse Solo Replacement Cartridge Original 4.8%.

We are disappointed in this decision. We are pursuing appropriate legal avenues in order to allow Vuse to continue offering its innovative products to adult nicotine consumers age 21+ without interruption. Although we disagree with the FDA’s decision, we remain committed to working alongside the agency to create A Better Tomorrow™.

Thank you for your patience as we navigate this process. We will continue to provide important updates as additional information becomes available.

The Vuse Team